Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2024.01.013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Eyal Grunebaum und 40 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: eyal.grunebaum@sickkids.ca. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Hematopoietic Stem Cell Transplantation, NADPH Oxidases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: P47phox (neutrophil cytosolic factor-1) deficiency is the most common cause of autosomal recessive chronic granulomatous disease (CGD) and is considered to be associated with a milder clinical phenotype. Allogeneic hematopoietic cell transplantation (HCT) for p47phox CGD is not well-described. OBJECTIVES: We sought to study HCT for p47phox CGD in North America. METHODS: Thirty patients with p47phox CGD who received allogeneic HCT at Primary Immune Deficiency Treatment Consortium centers since 1995 were included. RESULTS: Residual oxidative activity was present in 66.7% of patients. In the year before HCT, there were 0.38 CGD-related infections per person-years. Inflammatory diseases, predominantly of the lungs and bowel, occurred in 36.7% of the patients. The median age at HCT was 9.1 years (range 1.5-23.6 years). Most HCTs (90%) were performed after using reduced intensity/toxicity conditioning. HCT sources were HLA-matched (40%) and -mismatched (10%) related donors or HLA-matched (36.7%) and -mismatched (13.3%) unrelated donors. CGD-related infections after HCT decreased significantly to 0.06 per person-years (P = .038). The frequency of inflammatory bowel disease and the use of steroids also decreased. The cumulative incidence of graft failure and second HCT was 17.9%. The 2-year overall and event-free survival were 92.3% and 82.1%, respectively, while at 5 years they were 85.7% and 77.0%, respectively. In the surviving patients evaluated, ≥95% donor myeloid chimerism at 1 and 2 years after HCT was 93.8% and 87.5%, respectively. CONCLUSIONS: Patients with p47phox CGD suffer from a significant disease burden that can be effectively alleviated by HCT. Similar to other forms of CGD, HCT should be considered for patients with p47phox CGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Allergy, Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: eyal.grunebaum@sickkids.ca.
- Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, Md.
- Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wis; Center for International Blood and Marrow Transplant Research, Milwaukee, Wis.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Ga.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; P…
- Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- Intramural NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Office of Naval Research
Zitieren
APA
Grunebaum, E., Arnold, D. E., Logan, B., Parikh, S., Marsh, R. A., Griffith, L. M., Mallhi, K., Chellapandian, D., Lim, S. S., Deal, C. L., Kapoor, N., Murguía-Favela, L., Falcone, E. L., Prasad, V. K., Touzot, F., Bleesing, J. J., Chandrakasan, S., Heimall, J. R., Bednarski, J. J., …, & Leiding, J. W. (2024). Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.01.013
Vancouver
Grunebaum E, Arnold DE, Logan B, Parikh S, Marsh RA, Griffith LM, et al. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2024.01.013
BibTeX
@article{Grunebaum2024,
author = {Grunebaum, Eyal and Arnold, Danielle E and Logan, Brent and Parikh, Suhag and Marsh, Rebecca A and Griffith, Linda M and Mallhi, Kanwaldeep and Chellapandian, Deepak and Lim, Stephanie Si and Deal, Christin L and Kapoor, Neena and Murguía-Favela, Luis and Falcone, Emilia Liana and Prasad, Vinod K and Touzot, Fabien and Bleesing, Jack J and Chandrakasan, Shanmuganathan and Heimall, Jennifer R and Bednarski, Jeffrey J and Broglie, Larisa A and Chong, Hey Jin and Kapadia, Malika and Prockop, Susan and Dávila Saldaña, Blachy J and Schaefer, Edo and Bauchat, Andrea L and Teira, Pierre and Chandra, Sharat and Parta, Mark and Cowan, Morton J and Dvorak, Christopher C and Haddad, Elie and Kohn, Donald B and Notarangelo, Luigi D and Pai, Sung-Yun and Puck, Jennifer M and Pulsipher, Michael A and Torgerson, Troy R and Malech, Harry L and Kang, Elizabeth M and Leiding, Jennifer W},
title = {Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2024.01.013}
}
EUVIMED